Trial reportPloS one2015
Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00995163 (Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D)
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.European journal of epidemiology · 2017Pooled it
- Pooled it
- Effects of telmisartan and losartan treatments on bone turnover markers in patients with newly diagnosed stage I hypertension.Journal of the renin-angiotensin-aldosterone system : JRAASTrial
- Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review.Endocrine journal · 2025Review
- The impact of Renin-Angiotensin System Inhibitors on bone fracture risk: a nationwide nested case-control study.BMC musculoskeletal disorders · 2024Article
- Analysis of peri-implant bone tissue between hydrophilic and rough implant surfaces in spontaneously hypertensive rats treated with losartan.Journal of applied oral science : revista FOB · 2024Article
- Bone Disease in Chronic Kidney Disease and Kidney Transplant.Nutrients · 2022Review
- Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.Clinical and experimental nephrology · 2022Review
- Muscle-bone axis in children with chronic kidney disease: current knowledge and future perspectives.Pediatric nephrology (Berlin, Germany) · 2021Review
- The Embryonic Chick Femur Organotypic Model as a Tool to Analyze the Angiotensin II Axis on Bone Tissue.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Activation of (pro)renin by (pro)renin receptor in extracellular vesicles from osteoclasts.Scientific reports · 2021Article
- Bone Fragility Fractures in CKD Patients.Calcified tissue international · 2021Review
- Observational
- A Review of Pharmacology, Toxicity and Pharmacokinetics of 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside.Frontiers in pharmacology · 2021Review
- Type I Angiotensin II Receptor Blockade Reduces Uremia-Induced Deterioration of Bone Material Properties.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Article
- Inhibition of tanshinone IIA on renin activity protected against osteoporosis in diabetic mice.Pharmaceutical biology · 2020Article
- Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats.Journal of applied oral science : revista FOB · 2019Article
- Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study.International urology and nephrology · 2018Article
- Uremic Toxicity and Bone in CKD.Journal of nephrology · 2017Review
- Chronic kidney disease and fragility fracture.Clinical and experimental nephrology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic kidney disease, especially those undergoing dialysis treatment and having secondary hyperparathyroidism, have a high risk of bone fracture. The renin-angiotensin system (RAS) is associated with osteoclastic bone resorption. We aimed to examine whether the use of RAS inhibitors reduces the incidence of fracture in hemodialysis patients. METHODS AND
findingsThis was a multicenter, 3-year, prospective, observational study. From 2008 to 2011, maintenance hemodialysis patients with secondary hyperparathyroidism (N = 3,276) treated with angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) at baseline were followed for a mean of 2.7 years. The association between the use of ACEI/ARB and hospitalization rate owing to fracture was examined by using Cox regression models. Effect modifications by the severity of secondary hyperparathyroidism (intact parathyroid hormone [iPTH] level), sex, and systolic blood pressure were also examined. The incidence proportion of fracture-related hospitalization was 5.42% throughout the observation period. ACEI/ARB use was associated with a lower rate of fracture-related hospitalization (adjusted hazard ratio, 0.65; 95% confidence interval [CI], 0.45-0.92). This association was not significantly affected by sex (P = 0.56) or systolic blood pressure levels (P = 0.87). The hazard ratios adjusted by iPTH levels were qualitatively different, but not statistically significant (P = 0.11): 0.77 (95% CI, 0.42-1.39), 0.38 (95% CI, 0.20-0.73), 0.59 (95% CI, 0.29-1.21), and 1.29 (95% CI, 0.58-2.42) for the first, second, third and fourth quartiles of iPTH, respectively.
conclusionsUse of RAS inhibitors is associated with a lower rate of fracture-related hospitalization in hemodialysis patients with secondary hyperparathyroidism.
trial registrationClinicalTrials.gov NCT00995163.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.